The Greater Manchester spinout secured the capital from backers including The North West Fund for Biomedical and Central Manchester Foundation Trust to fund pre-clinical trials.
"Manchester is committed to its strategic and operational support for business growth and Co Angel Investment are just one of the services we have supported which is making a difference. We knew when we launched Co that Manchester held huge potential for a better, lower risk investment platform: the growing businesses like Gelexir are here, the Angels are here and now we have the infrastructure to bring them together to release further potential in the region."
The funding round was backed by Co Angel, The North West Fund for Biomedical, and the Central Manchester Foundation Trust.
"The team at Co have been instrumental as part of the process to date in giving strong and impartial advice, providing us links to potential investors, and generally supporting us in the fund raising process."
